Synthetic Bone Graft Substitutes Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Synthetic Bone Graft Substitutes Pipeline Market Report Overview

Synthetic bone graft substitutes are used as substitutes to autograft and allograft bone. Major types of synthetic bone substitutes include calcium sulfate, calcium phosphate, tricalcium phosphate (TCP), and coralline hydroxyapatite. The second-generation products include bioactive glass, collagen-containing and polymer-based bone substitutes. Products available in the form of granules, paste, pellets or strips are all tracked here. One unit volume is 10ml of synthetic bone substitutes.

The synthetic bone graft substitutes pipeline market research report provides comprehensive information about the synthetic bone graft substitutes pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.

Key Territories The US, Europe, China, Japan, and Taiwan
Key Regulatory Paths 510(k), PMA, CE, NMPA, TGA, Ninsho, and De Novo
Leading Companies Acuitive Technologies Inc, Agenta Biotechnologies Inc (Inactive), Amend Surgical, Inc., Anika Therapeutics Inc, Baxter International Inc, Berkeley Advanced Biomaterials Inc, Bio2 Technologies Inc, BioGend Therapeutics Co Ltd, Biomatlante SA, Biorez Inc, and BonAlive Biomaterials Ltd

Synthetic Bone Graft Substitutes Pipeline Market Segmentation by Territories

Some of the territories in the synthetic bone graft substitutes pipeline market are the US, Europe, China, Japan, and Taiwan among others. As of May 2023, the US has the highest number of pipeline products.

Synthetic Bone Graft Substitutes Pipeline Market Analysis, by Territories, 2023 (%)

Synthetic Bone Graft Substitutes Pipeline Market Analysis, by Territories, 2023 (%)

For more territory insights into the synthetic bone graft substitutes pipeline market, download a free report sample

Synthetic Bone Graft Substitutes Pipeline Market Segmentation by Regulatory Paths

Some of the regulatory paths in the synthetic bone graft substitutes pipeline market are 510(k), PMA, CE, NMPA, TGA, Ninsho, and De Novo among others. As of May 2023, 510(k) is the most followed pathway for pipeline products.

Synthetic Bone Graft Substitutes Pipeline Market Analysis, by Regulatory Paths, 2023 (%)

Synthetic Bone Graft Substitutes Pipeline Market Analysis, by Regulatory Paths, 2023 (%)

For more regulatory path insights into the synthetic bone graft substitutes pipeline market, download a free report sample

Synthetic Bone Graft Substitutes Pipeline Market – Competitive Landscape

Some of the key companies in the synthetic bone graft substitutes pipeline market are Acuitive Technologies Inc, Agenta Biotechnologies Inc (Inactive), Amend Surgical, Inc., Anika Therapeutics Inc, Baxter International Inc, Berkeley Advanced Biomaterials Inc, Bio2 Technologies Inc, BioGend Therapeutics Co Ltd, Biomatlante SA, Biorez Inc, and BonAlive Biomaterials Ltd among others.

Acuitive Technologies Inc: Acuitive Technologies Inc (Acuitive Technologies) is a developer of surgical medical devices designed to help in surgeries. It is headquartered in Allendale, New Jersey, the US. Citrefoam is developed by Acuitive Technologies. It is a synthetic porous sponge intended for bone healing. It is designed to fill bone voids of various sizes and promote bone healing. It is based on CITREGEN Technology.

Segments Covered in the Report

Synthetic Bone Graft Substitutes Pipeline Market Territories Outlook

  • The US
  • Europe
  • China
  • Japan
  • Australia
  • Taiwan

Synthetic Bone Graft Substitutes Pipeline Market Regulatory Paths Outlook

  • 510(k)
  • PMA
  • CE
  • NMPA
  • TGA
  • Ninsho
  • De Novo

Scope

  • Extensive coverage of the synthetic bone graft substitutes under development
  • Reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • Reviews the major players involved in the development of synthetic bone graft substitutes and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to Buy

The report enables you to:

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
  • Identify and understand important and diverse types of synthetic bone graft substitutes under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product’s current stage of development, territory and estimated launch date

Acuitive Technologies Inc
Agenta Biotechnologies Inc (Inactive)
Amend Surgical, Inc.
Anika Therapeutics Inc
Baxter International Inc
Berkeley Advanced Biomaterials Inc
Bio2 Technologies Inc
BioGend Therapeutics Co Ltd
Biomatlante SA
Biorez Inc
BonAlive Biomaterials Ltd.
Bone Solutions Inc
BoneGrafix, Inc.
BoneSupport AB
Calcitec, Inc.
Daewoong Pharmaceutical Co Ltd
Dimension Inx LLC
DSM Biomedical BV
Elute Inc
Eskisehir Osmangazi University
EternoGen Aesthetics LLC
Graftys SA
Industrie Biomediche Insubri SA
Innovoss Inc. (Inactive)
IRCCS San Raffaele Hospital
Isto Biologics
King's College London
Maxigen Biotech Inc
National Center of Innovation for Biomaterials in Orthopaedic Research
National University of Science and Technology MiSiS
OrthoMedex LLC
PolyPid Ltd
Polytechnic University of Catalonia
Promimic AB
ReCaPP
RepRegen Ltd. (Inactive)
Revivicor Inc
Sanara MedTech Inc
Scil Technology GmbH
SDIP Innovations Pty Ltd
SIRAKOSS Ltd
Sofregen Medical Inc
Soteira Inc
Sree Chitra Tirunal Institute for Medical Sciences & Technology
SurGenTec LLC
University of California San Diego
University of Edinburgh
Wright Medical Group NV (Inactive)
Xtant Medical Holdings Inc

Table of Contents

1 Table of Contents 3

1.1 List of Tables 7

1.2 List of Figures 11

2 Introduction 12

2.1 Synthetic Bone Graft Substitutes Overview 12

3 Products under Development 13

3.1 Synthetic Bone Graft Substitutes – Pipeline Products by Stage of Development 13

3.2 Synthetic Bone Graft Substitutes – Pipeline Products by Territory 14

3.3 Synthetic Bone Graft Substitutes – Pipeline Products by Regulatory Path 15

3.4 Synthetic Bone Graft Substitutes – Pipeline Products by Estimated Approval Date 16

3.5 Synthetic Bone Graft Substitutes – Ongoing Clinical Trials 17

4 Synthetic Bone Graft Substitutes – Pipeline Products under Development by Companies 18

4.1 Synthetic Bone Graft Substitutes Companies – Pipeline Products by Stage of Development 18

4.2 Synthetic Bone Graft Substitutes – Pipeline Products by Stage of Development 20

5 Synthetic Bone Graft Substitutes Companies and Product Overview 22

5.1 Acuitive Technologies Inc Company Overview 22

5.1.1 Acuitive Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 22

5.2 Agenta Biotechnologies Inc (Inactive) Company Overview 23

5.2.1 Agenta Biotechnologies Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 23

5.3 Amend Surgical, Inc. Company Overview 24

5.3.1 Amend Surgical, Inc. Pipeline Products & Ongoing Clinical Trials Overview 24

5.4 Anika Therapeutics Inc Company Overview 25

5.4.1 Anika Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 25

5.5 Baxter International Inc Company Overview 27

5.5.1 Baxter International Inc Pipeline Products & Ongoing Clinical Trials Overview 27

5.6 Berkeley Advanced Biomaterials Inc Company Overview 28

5.6.1 Berkeley Advanced Biomaterials Inc Pipeline Products & Ongoing Clinical Trials Overview 28

5.7 Bio2 Technologies Inc Company Overview 30

5.7.1 Bio2 Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 30

5.8 BioGend Therapeutics Co Ltd Company Overview 33

5.8.1 BioGend Therapeutics Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 33

5.9 Biomatlante SA Company Overview 38

5.9.1 Biomatlante SA Pipeline Products & Ongoing Clinical Trials Overview 38

5.10 Biorez Inc Company Overview 39

5.10.1 Biorez Inc Pipeline Products & Ongoing Clinical Trials Overview 39

5.11 BonAlive Biomaterials Ltd. Company Overview 40

5.11.1 BonAlive Biomaterials Ltd. Pipeline Products & Ongoing Clinical Trials Overview 40

5.12 Bone Solutions Inc Company Overview 41

5.12.1 Bone Solutions Inc Pipeline Products & Ongoing Clinical Trials Overview 41

5.13 BoneGrafix, Inc. Company Overview 44

5.13.1 BoneGrafix, Inc. Pipeline Products & Ongoing Clinical Trials Overview 44

5.14 BoneSupport AB Company Overview 45

5.14.1 BoneSupport AB Pipeline Products & Ongoing Clinical Trials Overview 45

5.15 Calcitec, Inc. Company Overview 50

5.15.1 Calcitec, Inc. Pipeline Products & Ongoing Clinical Trials Overview 50

5.16 Daewoong Pharmaceutical Co Ltd Company Overview 51

5.16.1 Daewoong Pharmaceutical Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 51

5.17 Dimension Inx LLC Company Overview 52

5.17.1 Dimension Inx LLC Pipeline Products & Ongoing Clinical Trials Overview 52

5.18 DSM Biomedical BV Company Overview 53

5.18.1 DSM Biomedical BV Pipeline Products & Ongoing Clinical Trials Overview 53

5.19 Elute Inc Company Overview 54

5.19.1 Elute Inc Pipeline Products & Ongoing Clinical Trials Overview 54

5.20 Eskisehir Osmangazi University Company Overview 55

5.20.1 Eskisehir Osmangazi University Pipeline Products & Ongoing Clinical Trials Overview 55

5.21 EternoGen Aesthetics LLC Company Overview 56

5.21.1 EternoGen Aesthetics LLC Pipeline Products & Ongoing Clinical Trials Overview 56

5.22 Graftys SA Company Overview 57

5.22.1 Graftys SA Pipeline Products & Ongoing Clinical Trials Overview 57

5.23 Industrie Biomediche Insubri SA Company Overview 59

5.23.1 Industrie Biomediche Insubri SA Pipeline Products & Ongoing Clinical Trials Overview 59

5.24 Innovoss Inc. (Inactive) Company Overview 60

5.24.1 Innovoss Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 60

5.25 IRCCS San Raffaele Hospital Company Overview 61

5.25.1 IRCCS San Raffaele Hospital Pipeline Products & Ongoing Clinical Trials Overview 61

5.26 Isto Biologics Company Overview 62

5.26.1 Isto Biologics Pipeline Products & Ongoing Clinical Trials Overview 62

5.27 King’s College London Company Overview 63

5.27.1 King’s College London Pipeline Products & Ongoing Clinical Trials Overview 63

5.28 Maxigen Biotech Inc Company Overview 64

5.28.1 Maxigen Biotech Inc Pipeline Products & Ongoing Clinical Trials Overview 64

5.29 National Center of Innovation for Biomaterials in Orthopaedic Research Company Overview 65

5.29.1 National Center of Innovation for Biomaterials in Orthopaedic Research Pipeline Products & Ongoing Clinical Trials Overview 65

5.30 National University of Science and Technology MiSiS Company Overview 66

5.30.1 National University of Science and Technology MiSiS Pipeline Products & Ongoing Clinical Trials Overview 66

5.31 OrthoMedex LLC Company Overview 67

5.31.1 OrthoMedex LLC Pipeline Products & Ongoing Clinical Trials Overview 67

5.32 PolyPid Ltd Company Overview 68

5.32.1 PolyPid Ltd Pipeline Products & Ongoing Clinical Trials Overview 68

5.33 Polytechnic University of Catalonia Company Overview 69

5.33.1 Polytechnic University of Catalonia Pipeline Products & Ongoing Clinical Trials Overview 69

5.34 Promimic AB Company Overview 70

5.34.1 Promimic AB Pipeline Products & Ongoing Clinical Trials Overview 70

5.35 ReCaPP Company Overview 71

5.35.1 ReCaPP Pipeline Products & Ongoing Clinical Trials Overview 71

5.36 RepRegen Ltd. (Inactive) Company Overview 72

5.36.1 RepRegen Ltd. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 72

5.37 Revivicor Inc Company Overview 74

5.37.1 Revivicor Inc Pipeline Products & Ongoing Clinical Trials Overview 74

5.38 Sanara MedTech Inc Company Overview 75

5.38.1 Sanara MedTech Inc Pipeline Products & Ongoing Clinical Trials Overview 75

5.39 Scil Technology GmbH Company Overview 76

5.39.1 Scil Technology GmbH Pipeline Products & Ongoing Clinical Trials Overview 76

5.40 SDIP Innovations Pty Ltd Company Overview 77

5.40.1 SDIP Innovations Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview 77

5.41 SIRAKOSS Ltd Company Overview 78

5.41.1 SIRAKOSS Ltd Pipeline Products & Ongoing Clinical Trials Overview 78

5.42 Sofregen Medical Inc Company Overview 81

5.42.1 Sofregen Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 81

5.43 Soteira Inc Company Overview 83

5.43.1 Soteira Inc Pipeline Products & Ongoing Clinical Trials Overview 83

5.44 Sree Chitra Tirunal Institute for Medical Sciences & Technology Company Overview 84

5.44.1 Sree Chitra Tirunal Institute for Medical Sciences & Technology Pipeline Products & Ongoing Clinical Trials Overview 84

5.45 SurGenTec LLC Company Overview 85

5.45.1 SurGenTec LLC Pipeline Products & Ongoing Clinical Trials Overview 85

5.46 University of California San Diego Company Overview 86

5.46.1 University of California San Diego Pipeline Products & Ongoing Clinical Trials Overview 86

5.47 University of Edinburgh Company Overview 87

5.47.1 University of Edinburgh Pipeline Products & Ongoing Clinical Trials Overview 87

5.48 Wright Medical Group NV (Inactive) Company Overview 88

5.48.1 Wright Medical Group NV (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 88

5.49 Xtant Medical Holdings Inc Company Overview 89

5.49.1 Xtant Medical Holdings Inc Pipeline Products & Ongoing Clinical Trials Overview 89

6 Synthetic Bone Graft Substitutes- Recent Developments 90

6.1 May 11, 2023: Medtronic to announce financial results for its fourth quarter and full fiscal year 2023 90

6.2 May 08, 2023: Hoya announces consolidated financial results for the fiscal year ended March 31, 2023 90

6.3 May 04, 2023: NuVasive announces conference call and webcast of Q1 2023 results 90

6.4 May 03, 2023: Sanara MedTech announces Q1 earnings release and conference call dates 90

6.5 Apr 19, 2023: Anika to issue first quarter 2023 financial results on Tuesday, may 9, 2023 91

6.6 Apr 12, 2023: Medtronic has a layoff in California 91

6.7 Mar 29, 2023: Baxter to Host Annual Meeting of Stockholders in Virtual Format 91

6.8 Mar 28, 2023: Stryker announces Annual Meeting of Shareholders 91

6.9 Mar 16, 2023: Surgalign to Host its 2023 Annual Meeting of Shareholders on June 1, 2023 91

6.10 Mar 16, 2023: Medtronic joins in $25M funding round for home monitoring company 92

6.11 Mar 06, 2023: Anika Reports Fourth Quarter and Year-End Fiscal 2022 Financial Results 92

6.12 Feb 22, 2023: Sanara MedTech Announces Unaudited Preliminary Results for the Fourth Quarter and Full Year 2022 93

6.13 Feb 21, 2023: Anika to Issue Fourth Quarter and Year-End 2022 Financial Results on Monday, March 6, 2023 94

6.14 Feb 14, 2023: Spineway Reports Full Year 2022 Earnings 94

6.15 Feb 09, 2023: Baxter Reports Fourth-Quarter and Full-Year 2022 Results 95

6.16 Feb 09, 2023: Spineway announces 2022 annual results 97

6.17 Jan 31, 2023: Hoya Announces Fourth semi-annual financial statements 98

6.18 Jan 09, 2023: ATEC Announces Select Preliminary Financial 2022 Results, 2023 Guidance and Closing of Flexible, Non-Dilutive Debt Facility 99

6.19 Nov 23, 2022: Medtronic Reports Quarterly Earnings 101

6.20 Nov 22, 2022: Medtronic reports second quarter fiscal 2023 financial results 101

6.21 Nov 15, 2022: Medtronic Set to Announce Earnings on Tuesday 107

6.22 Nov 10, 2022: Surgalign aims to slash $30M from 2023 spending with planned layoffs 107

6.23 Nov 08, 2022: Anika Reports Third Quarter Fiscal 2022 Financial Results 107

6.24 Nov 07, 2022: NuVasive launches tube system and excavation micro for posterior spine surgery 109

6.25 Oct 25, 2022: Anika to Issue Third Quarter 2022 Financial Results on Tuesday, November 8, 2022 110

6.26 Oct 10, 2022: ATEC Announces Select Preliminary Third Quarter 2022 Financial Results and Raises Guidance 110

6.27 Oct 06, 2022: Integra LifeSciences appoints Harvinder Singh as Executive Vice President, President Of Co.”s International Business 111

6.28 Oct 06, 2022: Integra LifeSciences Announces Key Executive Appointment 111

6.29 Sep 28, 2022: PolyPid announces eligibility for European Medicines Agency centralized procedure for D-PLEX100 for the prevention of surgical site infections in abdominal surgery 111

6.30 Sep 12, 2022: NuVasive to Participate as Double Diamond Sponsor at Scoliosis Research Society Annual Meeting 112

6.31 Sep 07, 2022: Baxter to Host Third-Quarter 2022 Financial Results Conference Call for Investors 112

6.32 Sep 07, 2022: Medtronic to appear at September investor conferences 112

6.33 Sep 06, 2022: Sanara MedTech to Present at the Virtual MicroCap Leadership Summit 113

6.34 Aug 30, 2022: ATEC to Participate in Upcoming Investor Conferences 113

6.35 Aug 23, 2022: Medtronic reports first quarter fiscal 2023 financial results 113

6.36 Aug 23, 2022: Medtronic Announces Quarterly Earnings Results 116

6.37 Aug 16, 2022: Sanara MedTech Announces Second Quarter 2022 Results 119

6.38 Aug 10, 2022: Biogennix Reports Record Quarter and Half-Year Sales 120

6.39 Aug 04, 2022: ATEC Reports Second Quarter 2022 Financial Results and Increases Full-Year Revenue Guidance 120

6.40 Aug 03, 2022: Anika Reports Second Quarter Fiscal 2022 Financial Results 121

6.41 Aug 02, 2022: Zimmer Biomet Announces Second Quarter 2022 Financial Results 124

6.42 Jul 28, 2022: Smith+Nephew Second Quarter and First Half 2022 Results 125

6.43 Jul 28, 2022: Balfour Beatty teams up with Steps to Hope to raise funds for people in need 126

6.44 Jul 26, 2022: ATEC to Participate in Upcoming Investor Conferences 126

6.45 Jul 21, 2022: ATEC to Report Second Quarter 2022 Financial Results on August 4 2022 127

6.46 Jul 12, 2022: Anika to Issue Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 127

6.47 Jun 27, 2022: Medtronic Board appoints Lidia Fonseca as a new director 127

6.48 Jun 10, 2022: Anika to Participate in the Sidoti Small Cap Virtual Investor Conference 128

6.49 Jun 08, 2022: Baxter to Host Second-Quarter 2022 Financial Results Conference Call for Investors 128

6.50 May 27, 2022: Medtronic reports full year and fourth quarter fiscal year 2022 financial results 128

6.51 May 26, 2022: Medtronic reports full year and fourth quarter fiscal year 2022 financial results announces 8% dividend increase 128

6.52 May 25, 2022: Baxter Highlights Business Strategies and Innovation at 2022 Investor Conference 129

6.53 May 25, 2022: ATEC to Host Investor Day, May 25, 2022 129

7 Appendix 130

7.1 Methodology 130

7.2 About GlobalData 133

7.3 Contact Us 133

7.4 Disclaimer 133

Frequently asked questions

Synthetic Bone Graft Substitutes Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies thematic reports
Currency USD
$4,000

Can be used by individual purchaser only

$12,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Synthetic Bone Graft Substitutes Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Synthetic Bone Graft Substitutes Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies in real time.

  • Access a live Synthetic Bone Graft Substitutes Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.